Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET scans may improve chemo decisions for abdominal cancer patients

NCT ID NCT06144853

Knowledge-focused Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study looked at whether repeated FDG-PET/CT scans can help select patients and evaluate how well a special chemotherapy (PIPAC) works for cancer that has spread to the lining of the abdomen. 34 patients with various abdominal cancers were included. The goal was to see if the scans could detect metabolic changes in tumors after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FDG-PET/CT scan
What this could lead to
If successful, this could show that PET scans are a useful tool to guide treatment decisions for people with abdominal cancer spread.
What could go wrong
This is a very small pilot study with only 34 participants, so results may not apply to everyone. It focuses on imaging, not on improving survival or symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

34 people

The number who actually took part.

Started

Mar 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

16 patients with peritoneal metastasis, four from each of the groups: gastric cancer, pancreatic cancer, colo-rectal cancer and ovarien cancer, eligebel for inclusion in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with synchronous or metachronous histology or cytology proven GC, PC, CRC, or OC with clinical evidence of PM. * Patients who are eligible for and offered PIPAC at the discretion of the dedicated multidisciplinary tumor conference and subsequent out-patient evaluation at Odense PIPAC Center * Patients with a maximum of one extra-peritoneal metastasis at CT dated within one month of inclusion. * Patients in Eastern Cooperative Oncology Group performance status 0-1. * Patients \>18 years of age. * Patients must be able to give mandatory oral and written consent in Danish. Exclusion Criteria: * Concomitant systemic chemotherapy (bidirectional treatment). * Known allergies to contrast dye. * Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial, or may influence the results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer digestive system cancer gastric cancer malignant pancreatic neoplasm ovarian cancer peritoneal carcinomatosis peritoneal neoplasm peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal cancer Peritoneal cancer Peritoneal carcinomatosis Peritoneal metastases

Contacts and locations

Locations

  • Odense PIPAC Center

    Odense, Funen, 5000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.